Clinical Trial Update: PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated PET imaging with Cu-64 labeled trastuzumab to visualize HER2-positive metastatic breast cancer, and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Cu-64 labeled trastuzumab (trastuzumab (Cu-64 radiolabeled))
• Herceptin (trastuzumab) (trastuzumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED